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Abstract
Background: Multiple sclerosis (MS) is a complex trait in which genes in the MHC class II region
exert the single strongest effect on genetic susceptibility. The principal MHC class II haplotype that
increases MS risk in individuals of Northern European descent are those that bear HLA-DRB1*15.
However, several other HLA-DRB1 alleles have been positively and negatively associated with MS
and each of the main allelotypes is composed of many sub-allelotypes with slightly different
sequence composition. Given the role of this locus in antigen presentation it has been suggested
that variations in the peptide binding site of the allele may underlie allelic variation in disease risk.
Methods: In an investigation of 7,333 individuals from 1,352 MS families, we assessed the
nucleotide sequence of HLA-DRB1 for any effects on disease susceptibility extending a recently
published method of statistical analysis for family-based association studies to the particular
challenges of hyper-variable genetic regions.
Results: We found that amino acid 60 of the HLA-DRB1 peptide sequence, which had previously
been postulated based on structural features, is unlikely to play a major role. Instead, empirical
evidence based on sequence information suggests that MS susceptibility arises primarily from amino
acid 13.
Conclusion: Identifying a single amino acid as a major risk factor provides major practical
implications for risk and for the exploration of mechanisms, although the mechanism of amino acid
13 in the HLA-DRB1 sequence's involvement in MS as well as the identity of additional variants on
MHC haplotypes that influence risk need to be uncovered.
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Multiple sclerosis (MS) is a common inflammatory
disease of the central nervous system characterized by
myelin loss, axonal pathology and progressive neurolo-
gical dysfunction [1]. The aetiology of MS is unknown,
but it is clear that both genetic and environmental
components are important [2].
The only consistent genetic association with MS in
Northern Europeans had been with extended MHC
haplotypes especially those containing HLA-
DRB1*1501 [3]. Recently, the interleukin 7 receptor
(IL7R) interleukin 2 receptor (IL2R), ecotropic viral
integration site 5 (EVI5) [4] and kinesin family member
1B (KIF1B) [5] genes have been shown to be additional
MS susceptibility loci [3, 6, 7]. However, the MHC is the
largest contributor to MS risk [3].
The association between MS and MHC class II has been
fine mapped to the extended haplotype HLA-
DQA1*0102-DQB1*0602-DRB1*1501-DRB5*0101 [8].
Intense linkage disequilibrium within the MHC has
prevented the exact susceptibility locus from being
identified. Analysis of the MHC region with a large
number of markers as well as classical typing show
evidence fortheinvolvementoftheclass IIregiononly[9,
10]. Theparadigmis more complex than oneinwhich the
HLA-DRB1*15 allele acts solely to increase MS risk. Our
previous investigations have shown that HLA-DRB1*15
and HLA-DRB1*17 bearing haplotypes increase risk of
MS, while HLA-DRB1*14 and HLA-DRB1*11 bearing
haplotypes are protective [11, 12]. Additionally, HLA-
DRB1*10, DRB1*01,a n dDRB1*08 interact with HLA-
DRB1*15 to influence disease risk [11, 12].
MHC class II molecules present antigen to CD4
+ Th e l p e r
cells and are integral to successful maintenance of self
tolerance by the immune system and the adaptive
immune response to invading pathogens [13]. Each
HLA-DRB1 allele forms, by the presence of defined
amino acid anchors, a number of specific pockets
comprising a peptide binding groove [14]. Different
HLA-DRB1 alleles may thus have different binding
affinities for disease-related peptides as determined by
their protein sequence, subsequently influencing com-
position of T cell repertoires, ultimately resulting in HLA-
DRB1 alleles having varying effects on disease risk.
However, protein sequence analysis has failed to provide
clarity. Class II alleles in MS patients are structurally no
different to those in healthy controls [15]. While some
studies have suggested that variable residues in the DR
beta chain may determine MS susceptibility [16-18],
others found no evidence that MS pathogenesis is
mediated by allele overlapping antigen binding sites
[19]. However, these studies were based on a relatively
small number of individuals and, thus, may have been
underpowered to detect any relevant effects [11, 12].
More recently, Barcellos et al. [ 2 0 ] ,b ya l i g n i n gt h e
protein sequences of HLA-DRB1*1501, *1503, *1701,
*0401, *0801,a n d*0803 with that of HLA-
DRB1*140101, *140102, *140103,a n d*1404 have
s u g g e s t e dt h a tt h ea m i n oa c i da tp o s i t i o n6 0o ft h e
HLA-DRB1 protein sequence determines the effect of a
HLA-DRB1 allele on MS susceptibility. This model however
does not take into account other HLA-DRB1 resistance
alleles, notably HLA-DRB1*11, *10 and *01 [12].
The HLA-DRB1 gene is unusual in that many loci in the
coding sequence can have any one of the four nucleo-
tides depending on the allelotype. Thus, empirical
studies were difficult, first, because such variability
requires large sample sizes, but – even more importantly
– because most traditional statistical methods are
limited to the more typical case of bi-allelic loci. We
present here the largest systematic investigation to date
and an extended more sensitive statistical approach,
which, for the first time, will allow us to determine
empirically whether or not the nucleotide or protein
sequence of HLA-DRB1 can account for allelic suscept-
ibility to MS.
Methods
Particpants
All participants in the study were ascertained through the
ongoing Canadian Collaborative Project on the Genetic
Susceptibility to MS (CCPGSMS), for which the meth-
odology has been previously described [21].
Genotyping
Total genomic DNA, extracted from whole blood as part
of the CCPGSMS, was used to type HLA-DRB1 alleles by
an allele-specific PCR amplification method [22]. All
genotypes were generated blind to pedigree structure and
disease status of the individual. Initially, HLA-DRB1
alleles were classified into 10 categories, HLA-DRB1*01
to HLA-DRB1*10. Four of them were then subdivided,
*05 into *11/12, *06 into *13/14, *02 into *15/16, and
*03 into *17/18. Since then, these "two-digit" genotypes
have been refined by adding two or four more digits. The
first two digits describe the type, which corresponds to
the serological antigen carried by an allelotype. The third
and fourth digits are used to list the allele subtypes,
numbers being assigned in the order in which the DNA
sequences were determined. Alleles whose numbers
differ in the first four digits must differ in one or more
nucleotide substitutions that change the amino acid
sequence of the encoded protein. Alleles that differ only
by synonymous nucleotide substitutions within the
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and sixth digits.
In our population, 24 PCRs were carried out to amplify
allelotypes corresponding to alleles HLA-DRB1*01, HLA-
DRB1*04, HLA-DRB1*07, HLA-DRB1*08, HLA-
DRB1*09, HLA-DRB1*10, HLA-DRB1*11,
HLA-DRB1*12, HLA-DRB1*13, HLA-DRB1*14, HLA-
DRB1*15, HLA-DRB1*16, HLA-DRB1*17,a n dHLA-
DRB1*18.E a c hHLA-DRB1 genotype was scored twice
by independent observers.
Sequence Information
HLA-DRB1 allele sequence information was obtained
from the Immunogenetics database of the European
Bioinformatics Institute [23]ftp://ftp.ebi.ac.uk/pub/data-
bases/imgt/mhc/hla/Alignments_Rel_2.21.zip, whose
nucleotide and amino acid numbering scheme will be
used here.
Statistical Analysis
For terrestrial life forms, the number of alleles per single
nucleotide polymorphism (SNP) is limited to five: A, C,
G, T, and X (deletion), although only two alleles have
been seen for most human SNPs. For HLA-DRB1 and
HLA-DRB2 SNPs, however, up to 4 and 5 nucleotides,
respectively, have been observed. As proven in [24], the
informative data for each bi-allelic parental mating type
(PMT) can be organized into three strata, with two
informative filial constellations each:
Mating Offspring Genotypes
A.A~A.C A.A A.C
A.C~A.C A.A C.C (A.C children are non-informative)
A.C~C.C A.C C.C
...
T.T~T.X T.T T.X
T.X~T.X T.T X.X (T.X children are non-informative)
T.X~X.X T.X X.X
With three alleles, only two constellations need to be
considered:
Mating Offspring Genotypes
A.A~C.G A.C A.G
A.C~A.G A.A A.C A.G C.G
...
X.X~T.G G.X T.X
X.G~X.T G.T G.X T.X X.X
With four or five alleles, each stratum contains four
informative filial genotypes, e.g.:
Mating Offspring Genotypes
A.C~G.T A.G, A.T C.G C.T
To determine, whether a particular allele confers risk,
children with this allele need to be 'paired' within the
same PMT stratum with children having the same
other allele. For bi-allelic PMTs, this leaves three
informative mating types per combination of alleles,
each with two informative filial genotypes [24]. For tri-
allelic PMTs, two situations may arise. One homo-
zygous parent, also yields only two filial genotypes,
while two heterozygous parents, yield strata with four
filial genotypes. For quad-allelic PMTs, both parents
are necessarily heterozygous yielding, again, four
possible filial genotypes.
After excluding non-informative children, all filial
genotypes within a PMT stratum have the same
expectation under the null hypothesis. Thus, for the
special case of bi-allelic parents, it has been suggested
[25] that the sign/McNemar test for exact ties be
applied [26], i.e. to count how often either of the
genes were transmitted, irrespective of the PMT.
Stratification [24] yields a test statistic based on counts
representing independently observed events (cases
born, rather than alleles transmitted, which are subject
to identical genetical and environmental confounders).
Here, the need for stratification is even more apparent
than for bi-allelic parents [27-29], as there are, for
instance, twice as many A alleles to be expected among
the children of A.C~A.G parents than either C or G
alleles.
When developing a test suitable for multi-allelic loci, it is
useful to note that the sign test can be written in the two
equivalent forms given at the ends of the following
equation:
ab
ab
ab
ab
a ab
ab
a ab
ab
b ab
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duals" a ab ab − + ( )
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22 and b ab ab − + ( )
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22 are sym-
metric, each follows asymptotically a standard Gaussian
distribution, allowing the contributions from different
PMT strata to be combined in an additive fashion.
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strata are informative:
Mating Informative Offspring Genotypes
A.A~A.x: A.A vs A.x
A.x~A.x: A.A vs x.x
A.x~x.x: A.x vs x.y
A.x~y.y: A.y vs x.y
A.x~A.y: A.A vs x.y
A.x~x.y: (A.x + A.y) vs (x.x + x.y)
A.y~x.y: (A.x + A.y) vs (x.y + y.y)
A.x~y.z: (A.y + A.z) vs (x.y + x.z)
The informative children A.A in the A.x~A.x and A.x~A.y
strata differ from the 'non-A' (x.x or x.y) counterparts by
two alleles. As in [24], this will be accounted for by
assigning twice the weight to these strata, rather than
assuming that the effects of the two alleles transmitted to
the same child are independently observed.
With more than two alleles, several comparisons could
be made within the A.x~A.y stratum, e.g.,
Mating Informative Offspring Genotypes
A.x~A.y: (A.A + A.y) vs (A.x + x.y)
A.x~A.y: (A.A + A.x) vs (A.y + x.y)
In both cases, the term to the left (A.A or A.x/A.y) would
have more A alleles than the corresponding term on the
right (A.x/A.y or x.y, respectively). Averaging across these
comparisons yields the same term (A.x+A.y)/2 on both
sides which, as the heterozygous children born to two
heterozygous children in the biallelic case, can be
ignored, resolving this seeming ambiguity. Again, strati-
fication is essential for developing a sound statistical
approach to deal with this complex situation.
From column card in Figure 1, the maximum number of
informative strata for the influence of a given allele is 3 ×
4 + 3 × 12 + 6 = 54 out of the 105. Of course, if a
particular PMT is not observed, the corresponding strata
need not be included. Column w gives the weight to be
applied to this stratum's contribution based on the
number of alleles differing.
This stratification now allows for different degrees of
'dominance' to be considered. An allele is "dominant" or
"recessive", if having a single copy confers the same risk
as having two copies or no copy, respectively.
When both parents are heterozygous for the allele of
interest, only those children are counted where both
alleles are equal to or different from the allele of interest
(n*=nA. A + n¬A.¬A). Thus, among these strata, the
e f f e c t i v es a m p l es i z ed e p e n d so nt h ea l l e l ec o n s i d e r e d .
Using the results of [30], the strata's contributions can be
combined into an allele-specific test statistic by forming
a single test statistic from the sum of the effect estimates
and their variances, respectively, e.g.,
T
wPMT n PMT n PMT PMT xyz
wPMT n
A
AA A C,G,T,X
A
=
+ − − () ∈ () ∑ ≠≠∈ {} ∑ || PMT
2 + + + − () ∈ () ∑ ≠≠∈ {} ∑
()
||
~, .
PMT n PMT PMT xyz
as
A A C,G,T,X
N
PMT
01
where x is the subset of the 54 PMTs informative
(relevant and not empty) for nucleotide A, while
n PMT A
+| and nAP M T
−| states the number of subjects
with a preponderance of A or non-A alleles, respectively
within the stratum indicated (i.e., nA. A, nA. x,o rnA.+,s e e
above).
From the above, nucleotide-specific test statistics can be
o b t a i n e db yp e r f o r m i n gt h ef o l l o w i n gs t e p s :
1) Select the PMTs where at least one parent is
heterozygous for the nucleotide considered (Figure 1).
2) Among the strata where both parents are heterozygous
for the nucleotide considered, eliminate the counts of
children that are also heterozygous for this nucleotide.
3) By number of parental copies of the nucleotide of
interest (1, 2, or 3), count the number of children with
more (1 or 2) vs the number of children with less (0 or 1,
respectively) alleles of this nucleotide.
4) Perform the stratified McNemar test [24] based on
these six numbers and the weights assigned to each of
A n PMT card rec w co w dom w
1 A.x~x.x ()
A.x x.x A.x x.x 1
A.x 22 2
nn nn n
++ −= ()
1
A.x 22 2
nn n − 40 11
A.x~y.y ()
A . yx . y A . yx . y 1
A.y 22 2
nn nn n
++ −= ()
1
A.x 22 2
nn n − 12 0 1 1
A.x~x.y ()
A.+ x.+ A.+ x.+ 1
A.+ 22 2
nn nn n
++ −= ()
1
A.+ 22 2
nn n − 12 0 1 1
A.x~y.z ()
A.+ x.+ A.+ x.+ 1
A.+ 22 2
nn nn n
++ −= ()
1
A.+ 22 2
nn n − 12 0 1 1
2A . x ~ A . x()
A.A x.x A.A x.x 1
A.A 22 2
nn nn n
++ −= ()
1
A.A 22 2
nn n
∗∗
− 41 2 1
A.x~A.y ()
A.A x.y A.A x.y 1
A.A 22 2
nn nn n
++ −= ()
1
A.A 22 2
nn n
∗∗
− 61 2 1
3A . A ~ A . x ()
A.A A.x A.A A.x 1
A.A 22 2
nn nn n
++ −= ()
1
A.A 22 2
nn n − 41 1 0
Figure 1
Standardized residuals by parental mating type
(PMT) with cardinality (card: number of
combinations of non-A nucleotides x, y, and z per
row) and weight (w: weight, depending on degree of
dominance).
BMC Medical Genetics 2009, 10:10 http://www.biomedcentral.com/1471-2350/10/10
Page 4 of 12
(page number not for citation purposes)the three categories of strata according to the degree of
dominance to be considered (Figure 1).
Software
Statistical analyses were done using S-PLUS 8.0 http://
www.insightful.com and the muStat library (available
from http://csan.insightful and http://cran.r-project.org).
Surface and cartoon representations were produced using
PyMOL http://www.pymol.org. The program VOLUMES
(R. Esnouf., unpublished data) was used with a 1.4 Å
radius probe to map the extent of the P4 pocket cavity.
Results
Of 7333 genotyped subjects, 3178 children (1773
affected and 1405 unaffected) from 1352 families (1–
15 children per family) had complete familial allele-type
and disease status information available.
Sequence analysis identified 93 SNPs that suffice to
characterize the differences between the 13 main allelic
types of HLA-DRB1.A ss h o w ni nT a b l e1 ,t h er e l a t i o n -
ship between nucleotides and allelic groups is complex.
Thus, characterizing subjects by the 13 allelic groups
(two-digit resolution) may not suffice to identify the
genetic factors contributing to disease susceptibility (or
resistance). For instance, for the second SNP (nucleotide
position (N) 016), HLA-DRB1*04 (T) is uniquely
different from all other groups (C), while the third
SNP (N037) separates HLA-DRB1*01, *15,a n d*16 (A)
from all other alleles (G). HLA-DRB1*09 is the only
allelic group characterized by a single allele at each of the
93 SNPs – all other allelotypes have genetic variability,
often with more than two alleles observed within each
allelic group at a given SNP. The region between N256
and N308 is characterized by various allelotypes with
three or four potential nucleotides per SNP.
This would render current statistical analysis strategies,
comparing one allelic group against all others, highly
inefficient. To resolve this conundrum, we extended a
recently developed statistical approach that allowed us
to assess at each of the 93 loci the association (controlled
for population admixture) with each individual nucleo-
tide (A, C, G, T, and deletion). The test statistics for this
analysis are shown in Table 2 (left side).
Traditionally, family-based association studies utilize infor-
mation from affected children only. With MS, however, the
unaffected siblings of cases can be reasonably assumed to
have similar genetic and environmental risk factors. Thus,
one can analyze the siblings in the same fashion as the
controls, after reversing the role of putative protective and
risk alleles. If a nucleotide at a particular locus confers a
risk, its absence should confer protection. The right side of
Table 2 shows that the genetic constellations seen in the
siblings,infact,closelyresembletheresultsseeninthecases,
thereby validating the results.
To be asymptotically equivalent with the TDT [25], the
stratified McNemar test [24], by default, assumes a co-
dominant model, doubling the weight of the homo-
zygous children born to two heterozygous parents. For
dominant and recessive alleles, homozygous children
(for the risk allele or the wild type, respectively) carry
either no or the same risk, respectively, as heterozygous
children, Thus, by assigning zero weight to some and
equal weights to other strata, one can shift the power
towards recessive and dominant models, respectively.
The results under the dominant, but not the recessive
model (data not shown) were similar to the results under
the co-dominance model, suggesting that individual
alleles contribute substantially to risk.
Based on these results, candidate loci for MS risk are (N =
nucleotide position, A = Amino acid position):
Position Nucleotide(s) Allelotype Carrying
Risk Nucleotide
N085: T HLA-DRB1*15
N124-126/A013: AGG HLA-DRB1*15/16
N375/A096: A HLA-DRB1*10/15/16
N390, 485, 511, A, T, A, A HLA-DRB1*15/16
585/A101-142:
Thus, the sequence variants of HLA-DRB1*15 that
increase MS risk can be narrowed down to these regions
(Figure 2). N085 is in the promoter region, A013 is part
of the antigen presentation P4 pocket, while A133-142
are part of the CD4 binding region [29]. (The region
from #33 (N196/A37) to #64 (N365/A93) has more
variability than the 13 categories can explain.)
Discussion
Multiple sclerosis is unambiguously associated with the
MHC class II region and this gene exerts the strongest
genetic effect on the risk of developing the disease [3].
We have shown that A013 is the key amino acid in
defining the risk of HLA-DRB1,y e tn om o l e c u l a ro r
functional explanation can be given for the dominant-
negative effects of *14 and *11, the complementary
effects of *08,a n dt h ep r o t e c t i v en a t u r eo f*01 and *10
i nt h ep r e s e n c eo f*15. It has been speculated that poor
engagement of the encephalitogenic peptide in the
context of *14 acts to alter the immune response in a
dominant-negative manner and thereby reduce the effect
of *15 [20]. Another explanation is that *14 binds one or
more peptides that can delete autoreactive T cells.
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(page number not for citation purposes)Table 1: Nucleotides (N#: nucleotide number, #A: amino acid number) found in 94 HLA-DRB1 SNPs discriminating the 13 main
two-digit allelic groups (rows)
Allelotype: 02 01 04 03 05 06 08 10 09 07
A# N# 15 16 17/18 11 12 13 14
-25 14 A A A A G G G G G G G AA
-24 16 C C C T CC C CCC C C C
-17 37 A A A G G G G G G G G G G
-16 41 C C C C T T T T T T T CC
-16 42 G G G T T T T T T T T T T
-1 85 T G G G G G G G G G G G G
-1 86 C C C C C C C C C C C C C
- 1 8 7 TTTTTT T TTT T T T
49 7 C C C C A A A A A A A CC
4 9 8 GGGGGG G GGG G A A
8 109 C C T T T T T T T T T T C
9 112 T T T G G G G G G G G A T
10 115 C C C C T T T T T T G CC
10 117 G G G G C C C C C C GG G
11 118 C C C G T T T T T T G G G
11 119 C C T T CC C CCC T A G
12 122 A A A A C C C C C C AA A
13 124 A A T C T T G T TG G T T T
13 125 G G T A C C G C CG G T T A
13 126 G G T T T T T T T T T T T
14 127 G G G G G G G G G G G G A
14 129 G G A GGG G GGG G G G
16 133 C C C C C C T C CT T CC C
19 144 T T T C TT T TTT C C C
26 164 T T T T AT T T TTT T A T
26 165 C C G CCC A CCC G T C
28 169 G G G G G G G G G G G C G
28 171 C C A C CG C G CG CG C A C A
30 175 T T T T T T C TTT C G C
30 176 A A G AAA A AAA G G T
31 178 T T A TTT T TTT G A T
32 181 T T T T C CT C CT CT CT C TT
33 184 A A A C AA A AAA A A A
34 189 G G A A G AG G AG AG AG A A G
37 196 T T T T AT AT CT AT AT TT A T
37 197 C C C AC AT AT T AT AT AT A A T
38 199 G G G G G G C GGG G G G
38 200 T T T T T T T T T T C TT
47 227 T AT A AT AT AT T AT AT A A A A
53 246 G G G G G G G G G G G G A
57 256 G G G AG GG G AG AG AG GG G
57 257 A A A AG AA AT ATG AC ATG A T T
57 258 CT C T CT TT CT CT CT CT T C C
58 260 C C C C C A CC C CC C C
58 261 CT T C CTG CG G C CT CTG CG C C C
60 265 T T T T T T T T CT TT T T
60 266 A A A A A A AC AC AA A C C
60 267 A A A A A A A A A A A A A
67 286 AC ACT AC ACT C ACT AT ACT ACT AT C T A
69 294 AG A G AG G AG A A AG A GG G
70 295 CG G C CG C CG G G CG G CCG
70 296 A A A A A A A A AG A G G A
70 297 G C G CG G CG C C CG C GG C
71 298 AG A AG AG A AG A AG AG A A A A
71 299 C G ACG AG A AG G AG AG G G G G
72 303 G CG GGGG CG CG GG CT GG
73 305 C C C C G CCC C CC C G
74 307 G G G CG C CG G CG CG CG GG C
74 308 C C C ACT AG ACT C CT ACT CT C A A
77 317 C C AC AC A CCCAC CC C C
77 318 C C CT C CT CCC C CC C C
78 320 A A A A A A A A A A A T AT
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(page number not for citation purposes)In this study, we performed the first empirical investiga-
tion of the nucleotide sequence of HLA-DRB1 with
respect to determining disease risk. The statistical
analysis employed in this study differs fundamentally
from previous analyses conducted in that it is based on
the actual nucleotides at a SNP, rather than HLA
allelotypes. In other words, it allows at each locus the
cases (or controls) to be categorized differently according
to the nucleotides observed. In principle, we might have
done the same analysis based on individual sequence
data, irrespective of the two- (four- or six-) digit allele
categories. In fact, using individual sequence data would
a v o i dt h ea m b i g u i t i e sw h i c hr e d u c e dt h es a m p l es i z et o
fewer than 300 for the SNPs between N196 and N372
(Table 2) due to some allelotypes having many different
nucleotides at these loci.
F o ra m i n oa c i d1 3 ,f o ri n s t a n c e ,w ec o u n tc a s e sw i t h
unambiguous parental mating type for the following
HLA-DRB1 allelotypes (see Table 3):
As the categories are refined or individual sequence data
becomes available, ambiguous cases will become fewer
or avoided altogether, respectively.
A si nt h ec a s eo fc a s e - c o n t r o ls t u d i e s[ 3 1 ] ,c o u n t i n g
alleles transmitted to cases, as suggested by [25] in the
Table 1: Nucleotides (N#: nucleotide number, #A: amino acid number) found in 94 HLA-DRB1 SNPs discriminating the 13 main
two-digit allelic groups (rows) (Continued)
78 321 C C CT CC CT CT C CT CC G CG
85 341 T T CT TT CT CT TTT T T T
86 344 TG T TG TG TG TG G TG TG TG TG T T
90 357 A A A AG A AG A AG A AG AA A
93 365 C C C C C C C C C C C A C
95 372 C C T CCC C CCC T CC
96 373 C C G T CC C CCC C C C
96 374 A A A A A A A A A A A A A
96 375 A A G T T T T T T T A T T
98 379 A A A G AA A AAA A G G
101 388 G G G G G G G G G G G G G
101 389 T T T T T T T T T T T T T
101 390 A A G G G G G G G G G G G
104 397 T T T G TT T TTT T G G
106 405 C C C C C C C C C C C T T
114 429 C C C C C C C C CG CC C C
117 438 C C C C T T T T T T T CC
120 446 G G G A GG G GGG A GG
133 484 C C C C C C C C C C C C C
133 485 T T G G G G G G G G G G G
133 486 G G G G G G G G G G G G G
134 489 C C C C T T T T T T CC C
140 505 G G G A A A A A A A A GG
142 511 A A G G G G G G G G G G G
142 512 T T T T T T T T T T T T T
142 513 G G G G G G G G G G G G G
145 522 A A A A A A G AAA G AA
149 534 G G G G C C C C C C GG G
152 543 C C T CCC C CCC C C C
166 583 C C C C C C C C C C C C C
166 584 G G G G G G G G G G A GG
166 585 A A G G G G G G G G G G G
169 594 G G G G G G G G G G G A A
179 624 C C T CCC C CCC T T T
180 625 G G G C GG G GGG G G G
181 629 C C C C C C C C C C T T T
181 630 A A G G AA A AAA G G G
190 656 A A A A A A A A A T AA A
207 707 T T C C TT T TTT T T T
218 739 C C C C C C C C C C C C T
232 783 A A A A A A A A A A C AA
234 789 C C C C G G G G G CC C C
#Cases: 3994 208 1396 1982 1873 1068 146 1519 243 408 80 98 1653
Note that many SNPs have more than two nucleotides and some SNPs have several nucleotides for the same allelic group. For instance, Nucleotide 257
canbeeitherAorTwithinallelotype*12andA,T,orGwithinallelotype*13.GiventhehighprevalenceoftheHLA-DRB1*15(15)allele,thenucleotide
found in this group of alleles was used as the reference, unless several nucleotides were found in the alleles constituting the HLA-DRB1*15 group.
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#N #A A C G T A C G T
1 14 -25 6.723 -6.723 1231 0.506 -0.506 995
2 16 -24 4.485 -4.485 747 0.512 -0.512 593
33 7 - 1 7 12.563 -12.563 1249 1.774 -1.774 1018
4 41 -16 6.723 -6.723 1231 0.506 -0.506 995
54 2 - 1 6 12.563 -12.563 1249 1.774 -1.774 1018
6 85 -1 -15.587 15.587 1139 -2.985 2.985 926
7 97 4 -6.723 6.723 1231 -0.506 0.506 995
8 98 4 -3.206 3.206 696 -1.308 1.308 547
9 109 8 11.817 -11.817 1311 1.629 -1.629 1028
10 112 9 -1.313 -9.607 9.830 1340 0.354 -0.829 0.776 1066
11 115 10 6.723 -1.000 -6.565 1245 0.506 0.316 -0.562 1004
12 117 10 -6.565 6.565 1236 -0.562 0.562 993
13 118 11 12.563 -6.002 -6.565 1544 1.774 -1.323 -0.562 1245
14 119 11 -1.313 7.597 -2.961 -6.254 1360 0.354 2.093 -1.418 -1.354 1073
15 122 12 6.565 -6.565 1236 0.562 -0.562 993
16 124 13 14.806 -5.027 -1.172 -9.371 1425 3.079 -0.726 0.884 -2.514 1133
17 125 13 -6.121 -5.444 13.465 -4.346 1507 -1.794 -0.856 3.240 -1.205 1225
18 126 13 15.117 -15.117 1171 2.781 -2.781 961
19 127 14 -2.961 2.961 657 -1.418 1.418 528
20 129 14 -3.750 3.750 544 -1.403 1.403 455
21 133 16 1.172 -1.172 236 -0.884 0.884 155
22 144 19 -6.002 6.002 1118 -1.323 1.323 897
23 164 26 0.156 41 0.730 -0.730 30
24 165 26 4.739 -3.887 -1.313 663 1.508 0.732 -1.289 0.354 531
25 169 28 -1.313 1.313 58 0.354 -0.354 32
26 171 28 -4.609 4.964 -1.732 395 -0.967 0.981 0.000 310
27 175 30 -3.790 -1.313 4.009 770 -0.885 0.354 0.792 617
28 176 30 5.203 -4.158 -2.961 1055 1.941 -1.169 -1.418 857
29 178 31 -4.029 -1.000 4.158 605 -1.277 0.316 1.169 505
30 181 32 -1.742 1.742 309 0.000 0.000 255
31 184 33 4.485 -4.485 747 0.512 -0.512 593
32 189 34 -5.998 5.998 425 -0.372 0.372 348
33 196 37 18 9
34 197 37 -1.897 3.130 -2.629 71 -0.333 1.386 -1.361 58
35 199 38 -2.438 2.438 88 1.508 -1.508 44
36 200 38 -1.000 1.000 36 0.316 -0.316 40
37 227 47 -4.743 4.743 116 -2.008 2.008 87
38 246 53 -2.961 2.961 657 -1.418 1.418 528
40 257 57 4.879 -4.879 208 3.048 -3.048 153
41 258 57 -1.121 1.121 29 -1.291 1.291 11
42 260 58 -4.929 4.929 461 0.246 -0.246 390
43 261 58 -0.775 0.000 1.134 9 0.258 0.000 -0.577 9
45 266 60 2.863 -2.863 488 2.066 -2.066 373
46 286 67 -0.447 0.447 5 -0.577 0.577 3
47 294 69 -0.956 0.956 67 -0.117 0.117 49
48 295 70 2.656 -2.656 69 0.289 -0.289 39
49 296 70 1.877 -1.877 92 -0.367 0.367 67
50 297 70 -6.363 6.363 428 -1.261 1.261 300
52 299 71 -0.884 4.447 -4.196 159 -0.717 2.535 -2.137 96
54 305 73 2.218 -2.218 1086 1.724 -1.724 903
55 307 74 -3.558 3.558 203 -2.571 2.571 139
56 308 74 -2.333 2.333 72 -1.477 1.477 55
57 317 77 -1.191 1.191 273 -0.931 0.931 186
59 320 78 1.121 -1.121 39 -0.426 0.426 22
60 321 78 2.183 -2.183 17 0.632 -0.632 10
62 344 86 -1.414 1.414 2 0.000 0.000 0
64 365 93 -1.313 1.313 58 0.354 -0.354 32
65 372 95 3.887 -3.887 566 1.289 -1.289 476
66 373 96 6.168 -3.750 -4.485 1085 1.428 -1.403 -0.512 880
67 375 96 14.920 -3.750 -12.385 1386 2.799 -1.403 -1.818 1135
68 379 98 5.914 -5.914 1106 1.400 -1.400 887
69 390 101 15.117 -15.117 1171 2.781 -2.781 961
70 397 104 -5.914 5.914 1106 -1.400 1.400 887
71 405 106 3.206 -3.206 696 1.308 -1.308 547
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has recently been proven to result in a suboptimal
analysis strategy even in the case of bi-allelic parents
[24], because the TDT's variance estimate is based, in
part, on the counts of non-informative heterozygous
children born to two heterozygous parents. As with
Student's t- vs. the Gauss' z-test (which are also
asymptotically equivalent), this additional variance
would need to be accounted for. The stratified McNemar
test [24], in contrast, avoids this problem by replacing
2×( nP. P + nP. Q + nQ. Q) in the denominator by 4 ×
(nP. P + nQ. Q). For tri- or tetra-allelic parents, stratifica-
tion is even more important, because it also leads to
novel analysis strategies.
Barcellos et al. [20] have suggested that amino acid 60
accounts for the protective effect of the HLA-DRB1*14
allele, because this locus is close to the P4 binding
pocket and HLA-DRB1*1401 encodes histidine (CAC),
while HLA-DRB1*1701, *0401, *0801 and *1501 all
encode tyrosine (TAC). Upon close inspection of the
SNP profiles, however, the observed relationship
between HLA-DRB1*15/*15, HLA-DRB1*15/*08 and
HLA-DRB1*14 seems to be more complex.
Among the 4-digit HLA-DRB1 allelotypes, the majority
of alleles code TAC for tyrosine, as does HLA-DRB1*15
(all 4-digit allelotypes).
Codon Four digit HLA-DRB1*14 allelotype
carrying codon
TAC (14xx): 02,03,05,06,09,11,12,13,14,15,17,18,19,
20,21,23,24,27,29,30,33,36,37,40,41,
42,43,44,45,36,47,51,52,56,57,59,63,
65,67,76,77
CAC (14xx): 01,04,07,08,10,16,22,25,26,28,31,32,34,
35,38,39,49,50,53,54,55,58,60,61,62,
68,69,70,71,72,73,74,75
TCC (14xx): 48,64
Table 2: Test statistics for specific alleles at any of the 93 SNPs increasing (positive) or decreasing (negative) the risk of MS (Continued)
73 438 117 6.723 -6.723 1231 0.506 -0.506 995
74 446 120 -4.595 4.595 769 -0.422 0.422 609
75 484 133 -15.117 15.117 1171 -2.781 2.781 961
76 489 134 6.565 -6.565 1236 0.562 -0.562 993
77 505 140 -9.607 9.607 1325 -0.829 0.829 1057
78 511 142 15.117 -15.117 1171 2.781 -2.781 961
79 522 145 2.573 -2.573 121 -1.342 1.342 82
80 534 149 -6.565 6.565 1236 -0.562 0.562 993
81 543 152 3.750 -3.750 544 1.403 -1.403 455
82 584 166 -1.000 1.000 36 0.316 -0.316 40
83 585 166 15.117 -15.117 1171 2.781 -2.781 961
84 594 166 -3.206 3.206 696 -1.308 1.308 547
85 624 179 5.203 -5.203 1003 1.941 -1.941 816
86 625 180 -4.485 4.485 747 -0.512 0.512 593
87 629 181 3.348 -3.348 718 1.199 -1.199 581
88 630 181 7.597 -7.597 1248 2.093 -2.093 999
89 656 190 -0.450 0.450 180 -0.616 0.616 132
90 707 207 -6.168 6.168 1032 -1.428 1.428 823
91 739 218 2.961 -2.961 657 1.418 -1.418 528
92 783 232 1.000 -1.000 36 -0.316 0.316 40
93 789 234 6.813 -6.813 1207 0.771 -0.771 989
Left side: analysis of cases, right side: analysis of unaffected siblings.
Figure 2
Position of candidate risk polymorphic residues in
HLA-DRB1*1501. a. Cartoon representation of HLA-
DRB1 (PDB ID 1BX2) in which the Ca atoms of candidate
risk polymorphic residues (Table 2) are represented as small
spheres (green). The b1a n db2 domains are labeled.
b. Surface and cartoon representation of HLA-DRB! viewed
from above the binding groove. The three-dimensional
arrangement of the P4 pocket is shown as a grey mesh. The
Ca atoms of the polymorphic residues 13 b ( g r e e n )a tt h e
base of the P4 pocket and residue 60 b (orange) are
represented as small spheres.
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genotyped at the 4-digit level. Among them, 82% were
*1401 and 9% were *1404. If one assumes that these
30% were representative and that the same proportion
holds for our population, H at P60 could exert its
"protective" effect in about 90% of all 14xx subjects.
However, the purported disease risk increasing TAC
codon is also seen in *0101, *0103, *0104, *0110,a n d
*0111. Thus, if this amino acid should cause *08 to have
its special role in *15/*08 heterozygous subjects, this
effect should be seen with other alleles, yet this is not the
case [11, 12].
For amino acid 13, instead, *15 (all K) is disjoint from
both *08 (all G/glycine) and *14 (mostly S/serine)
Codon HLA-DRB1 allelotype carrying codon
AGG/K (15xx): (all)
GGT/G (08xx): (all)
TCT/S (14xx): 01,02,03,05,06,07,08,09,12,13,14,16,
17,18,19,20,21,22,23,24,25,26,27,
32,33,34,35,36,37,38,39,40,41,42,
43,44,45,46,47,48,49,51,53,54,55,
56,58,59,60,62,63,64,65,66,67,69,
70,72,74,75,77
GGT/G (14xx): 04,11,15,28,29,30,50,52,61,68,71,73,
76,
CAT/H (14xx): 10,31,57
From this data, it seems unlikely that histidine at amino
acid 60 contributes substantially to the protective effect
of this haplotype. Instead, a m i n oa c i d1 3e m e r g e sa sa
more likely explanation for a disease association
gradient [32]. It is the only amino acid that shows
sufficient variation to explain a hierarchy of disease
associated alleles, raising the possibility that TCT/S is, in
fact, associated with protection, while GTT/G is asso-
ciated with increased risk. Being located right in the
center of the P4 binding pocket, amino acid 13 is a
residue that is potentially in contact with presented
peptides [29, 32]. Another interesting finding of this
paper is the implication that the promoter region, may
play an important role. This finding lends notion to the
idea of regulatory variants contributing to MS risk. As we
have previously shown [33], HLA-DRB1 (and therefore
amino acid 13) cannot fully explain the MHC class II
associated MS risk and these nearby variants remain to
be uncovered.
It has been argued that "low resolution allele grouping
[...] maximize [s] statistical power" [20', p. 2821] when
comparing one group against all others. When increasing
t h es a m p l es i z ec o m e sa tt h ee x p e n s eo fi n c r e a s i n g
within group variance, however, statistical power often
suffers. Let us assume that group *02 had not been
separated into *15 (3994 cases) and *16 (208) cases.
Then, according to Table 4, 208 'G' cases would have
been added to the 3,994 'T' cases to a total of 4202, but
the size of the 'G' group would have been reduced from
10,674 to 10,466. Even though the number of informa-
tive trios would slightly increase (from 1139 to 1171, see
Table 2), the test statistic would drop from 11.022 to
10.689. The proposed statistical test, in contrast, utilized
the information obtained through high resolution
allelotyping (or sequencing) to increase group sizes by
combining allelotypes with the same nucleotide at a
given locus.
As we have demonstrated above, introducing the concept
of stratification by parental mating type has not only
quantitative advantages [24] over the original more
simplistic approach, but also qualitatively different
results for SNPs with more than two alleles in the
population. As more data are collected, the proposed
method could even be extended to address the difference
between association (in trans) and protein function (in
cis). To do so, one could categorize filial genotypes by
pairs of amino acids, rather than nucleotides, so that
differences in nucleotides coding for the same protein
would be ignored. Of course, to ensure that genetic
confounders are eliminated, parental mating types
should still be defined based on the genetic code, rather
than the amino acid for which it is coding. While this
strategy is based on a large number of possible
combinations between three-nucleotide parental mating
types and combinations of filial amino acids, the
number of combinations observed at each locus is likely
to be substantially smaller.
Conclusion
In conclusion, an extended statistical approach allowed
us to identify A013 at the center of the P4 pocket of HLA-
DRB1 as a potentially important (although unlikely
exclusive) risk factor for MS.
Table 3:
Nucleotide N124 N125 N126
A: 15, 16 04, 07 -
C: 04 03, 11, 13 -
G: 12, 08 15, 16, 08 15, 16
T: 01, 03, 11, 13,
10, 09, 07
01, 10, 09 01, 04, 03, 11, 12, 13,
14, 08, 10, 09, 07d
ambiguous: 14 14
(numbers indicate HLA-DRB1 allelotype).
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